Par Sues FDA For Yanking Gout Drug's 180-Day Exclusivity
Par Pharmaceutical is suing the U.S. Food and Drug Administration in D.C. federal court over its revoked 180-day exclusivity period for a generic gout drug, saying the agency incorrectly deemed its...To view the full article, register now.
Already a subscriber? Click here to view full article